Anika Therapeutics Inc (NAS:ANIK)
$ 17.35 -0.2 (-1.14%) Market Cap: 254.10 Mil Enterprise Value: 219.27 Mil PE Ratio: 0 PB Ratio: 1.42 GF Score: 70/100

Anika Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2021 / 06:00PM GMT
Release Date Price: $39.8 (-1.92%)
Peter Harrison

Good afternoon, and thanks for joining us for Anika Therapeutics fireside chat. Joining me today is Cheryl Blanchard, CEO; and Mike Levitz, CFO. Before we get started, let me get rid of the required disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Great. With that behind us, and obviously, the portal is open for any questions you all may have. Let's get started.

Questions & Answers

Peter Harrison

Cheryl, I thought maybe we get started. Before we into details, maybe talk a little bit about Anika, who Anika is for those who are not as familiar with the story?

Cheryl R. Blanchard
Anika Therapeutics, Inc. - President, CEO & Director

Yes, absolutely. Thanks, Peter, and thanks for the invitation to allow us to continue to tell

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot